NMDA Modulation in Major Depressive Disorder
Who is this study for? Patients with major depressive disorder
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: f
View:
• Have a DSM-5 (American Psychiatric Association) diagnosis of MDD
• 17-item Hamilton Rating Scale for Depression total score ≥ 18
• Free of antidepressant drugs for at least 2 weeks
• Agree to participate in the study and provide informed consent
Locations
Other Locations
Taiwan
Department of Psychiatry, China Medical University Hospital
RECRUITING
Taichung
Contact Information
Primary
Hsien-Yuan Lane, M.D., Ph.D
hylane@gmail.com
886 4 22052121
Time Frame
Start Date: 2017-06-01
Estimated Completion Date: 2026-12
Participants
Target number of participants: 90
Treatments
Experimental: NMDAE
An NMDA enhancer
Active_comparator: SSRI
Sertraline (selective serotonin reuptake inhibitor)
Placebo_comparator: Placebo
Placebo
Related Therapeutic Areas
Sponsors
Collaborators: Ministry of Science and Technology, Taiwan
Leads: China Medical University Hospital